VALISONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VALISONE (VALISONE).
Betamethasone valerate is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), which control the release of arachidonic acid from membrane phospholipids, thereby inhibiting prostaglandin and leukotriene synthesis. It has anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Betamethasone valerate is metabolized primarily in the liver via CYP3A4 to its active metabolite, betamethasone. Further metabolism includes reduction and conjugation. |
| Excretion | Renal (primarily as metabolites, <5% unchanged); biliary/fecal elimination accounts for <10%. |
| Half-life | Approximately 1.7 hours after topical application; systemic half-life is short due to rapid metabolism. |
| Protein binding | Approximately 90% bound to plasma proteins. |
| Volume of Distribution | Not well defined for topical use; negligible systemic distribution due to low percutaneous absorption. |
| Bioavailability | Topical: <1% systemic bioavailability with intact skin; higher with damaged skin or occlusion. |
| Onset of Action | Topical: measurable vasoconstriction within 2-3 hours; clinical improvement in 24-48 hours. |
| Duration of Action | Topical: once-daily application maintains effect for 24 hours; systemic effects minimal. |
Topical: Apply a thin layer to affected skin once or twice daily. Maximum duration: 2 weeks.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for children under 12 years due to higher systemic absorption. |
| Geriatric use | Use with caution, apply minimal amounts for shortest duration due to increased risk of skin atrophy and systemic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VALISONE (VALISONE).
| Breastfeeding | Betamethasone valerate is excreted into human breast milk following topical application, but in negligible amounts. The M/P ratio is not established for topical use. Systemic absorption is minimal with appropriate use, making risk to nursing infant low. However, caution is advised: avoid application to breast area to prevent infant ingestion, and use lowest effective dose for shortest duration. The American Academy of Pediatrics considers topical corticosteroids compatible with breastfeeding. |
| Teratogenic Risk | Topical corticosteroids, including betamethasone valerate (Valisone), are considered to have a low risk of teratogenicity when used topically in recommended doses. However, systemic exposure can occur, especially with prolonged use on large areas, occluded skin, or damaged skin. In pregnancy, topical corticosteroids are classified as Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second and third trimesters: Use only if clearly needed; avoid chronic high-dose or widespread use. Animal studies show corticosteroids can cause cleft palate and growth retardation at high systemic doses. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to betamethasone valerate or any component of the formulation","Untreated bacterial, fungal, or viral infections at the application site","Perioral dermatitis","Rosacea"]
| Precautions | ["Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria.","Use with caution in pediatric patients as they may absorb proportionally larger amounts due to higher skin surface-to-body weight ratio.","Avoid use on face, groin, or axillae unless directed by physician; avoid prolonged use or occlusive dressings.","Local adverse reactions include skin atrophy, striae, telangiectasias, purpura, and secondary infection."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression in mother if large areas or occlusive dressings are used. For prolonged therapy or high doses, consider fetal growth monitoring via ultrasound. No specific fetal monitoring is required for short-term, low-dose topical use. |
| Fertility Effects | No direct studies on betamethasone valerate and human fertility. Systemic corticosteroids at high doses may affect fertility by altering hormone levels, but topical use is unlikely to impact fertility at recommended doses. |